You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -90.0 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 0.0 | 0.0 |
Price / Book value | 54.8 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2017-06-30 | n/a | 0.35 | 0.50p | 85.0 | 0.0 | n/a | n/a | 0.0% |
2018-06-30 | n/a | -1.72 | -2.50p | -16.0 | 0.0 | n/a | n/a | 0.0% |
2019-06-30 | n/a | -1.68 | -2.50p | -8.7 | 0.0 | n/a | n/a | 0.0% |
2020-06-30 | 0.05 | -1.12 | -1.50p | -17.5 | 0.0 | n/a | n/a | 0.0% |
2021-06-30 | n/a | -1.72 | -2.50p | -115.0 | 0.0 | n/a | n/a | 0.0% |
Sareum progresses Covid-19 and autoimmune treatment candidate Sharecast News | 16 Mar |
---|---|
Sareum expects FY losses to widen on higher R&D costs, supply delays Sharecast News | 19 Aug |
Sareum positive on SRA737 outlook after Sierra call Sharecast News | 06 Aug |
Sareum to Present at BioTrinity 2022 Conference | 26-Apr-22 07:00 |
---|---|
Sareum notes acquisition of Sierra Oncology by GSK | 13-Apr-22 16:04 |
Second Price Monitoring Extn | 13-Apr-22 11:07 |
Price Monitoring Extension | 13-Apr-22 11:02 |
European Patent Granted for Sareum’s SDC-1802 | 11-Apr-22 07:00 |